West Pharmaceutical Servs Stock (NYSE: WST)

West Pharmaceutical Servs Stock (NYSE:WST), Trade Ideas

West Pharmaceutical Servs

West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Wall Street bull

Analyst Color

Equities

Large Cap

Mid Cap

Sector ETFs

Broad U.S. Equity ETFs

New ETFs

Retail Sales

Small Cap

Econ #s

Economics

Federal Reserve

Intraday Update

Markets

Analyst Ratings

Tech

ETFs

CBRE

CSCO

SPDR Dow Jones Industrial Average ETF Trust

PEGA

PENN

TRIP

TSLA

TWLO

YETI

ZBRA

US stocks surge on strong earnings and speculation of Fed rate cuts. S&amp;P 500 rebounds past 5000, Nasdaq 100 pauses. Small caps outperform. Tesla, Wells Fargo, and CBRE rally on positive news while Deer &amp; Antero Resources shares drop. Other companies react to earnings.

S&amp;P Reclaims 5,000 As Disappointing Retail Sales Put Fed Cuts Back On Track, Small Caps Shine: What&#39;s Driving Markets Thursday?

News

Penny Stocks

Movers

Trading Ideas

AMWL

APPN

AUPH

CETY

CGNX

CHNR

CNVS

DNOW

DTSS

DWAC

ELWS

EPAM

EXPR

FROG

FSLY

IFBD

INFA

INOD

JXJT

LYFT

MANU

NNOX

NSIT

ORGS

PLCE

PTEN

RNLX

ROMA

RVSN

SABR

SHAK

SLVM

SOUN

SPWR

TELO

UDMY

ULBI

UPXI

Shares of  Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings.

Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

pharmacy ai

Earnings

Guidance

Health Care

Reiteration

General

West Pharmaceutical Services reports Q4 2023 adjusted EPS at $1.83, surpassing consensus. Quarterly sales hit $732 million missing estimates. 2024 guidance hints at moderated organic growth, emphasizing inventory management strategies.

West Pharmaceutical&#39;s 2024 Outlook Cautious, Analysts Remain Optimistic

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Services Inc

WEST HOLDINGS CORP by West Holdings Corp.

West Holdings Corp

WESTELL TECHS INC A NEW by Westell Technologies, Inc.

Westell Technologies Inc

WESTLIN CORP by Westlin Corp.

WESTERN URANIUM&VANADIUM by Western Uranium & Vanadium Corp.

Western Uranium & Vanadium Corp

WESTPORTS HLDGS BHD ORD by WESTPORTS HLDGS BHD

Westports Holdings Bhd

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has risen 8.42% since its last report. The company recently reported that it has 1.16 million shares sold short, which is 2.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711474214_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 4.79%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(WST) - Analyzing West Pharmaceutical Servs's Short Interest

Mark Eric Green, President at West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), reported acquisition of company stock options on February 22, according to a new SEC filing.
What Happened: Uncovered in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000105770/000112760224006385//Archives/edgar/data/105770/000112760224006385/0001127602-24-006385-index.htm">U.S. Securities and Exchange Commission</a>, Green, President at West Pharmaceutical Servs, executed an insider options move. This move consisted of acquiring stock options for 25,221 shares of WST, granting Green the right to purchase the company's stock at an exercise price of $350.18 per share.
Currently, West Pharmaceutical Servs shares are trading up 0.48%, priced at $361.63 during Friday's morning. This values Green's 25,221 shares at $288,780.
<h3>Discovering West Pharmaceutical Servs: A Closer Look</h3>
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
<h3>West Pharmaceutical Servs: Financial Performance Dissected</h3>
Revenue Growth: West Pharmaceutical Servs's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 3.29%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 38.01%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): West Pharmaceutical Servs's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 1.85.
</li>
</ul>
Debt Management: West Pharmaceutical Servs's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: West Pharmaceutical Servs's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 45.67.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 9.19 is above industry norms, reflecting an elevated valuation for West Pharmaceutical Servs's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 30.6 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000105770">Check Out The Full List Of West Pharmaceutical Servs's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Mark Eric Green Expands Holdings With $288K West Pharmaceutical Servs Stock Options Acquisition

A substantial acquisition of company stock options by Silji Abraham, SVP at West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) was reported on February 22, based on a new SEC filing.
What Happened: Disclosed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000105770/000112760224006389//Archives/edgar/data/105770/000112760224006389/0001127602-24-006389-index.htm">U.S. Securities and Exchange Commission</a>, Abraham, SVP at West Pharmaceutical Servs, made a strategic derivative acquisition. This involved acquiring stock options for 2,968 shares of WST, providing the right to buy the company's stock at an exercise price of $350.18 per share.
During Friday's morning session, West Pharmaceutical Servs shares down by 0.0%, currently priced at $359.9. Considering the current price, Abraham's 2,968 shares have a total value of $28,848.
<h3>Unveiling the Story Behind West Pharmaceutical Servs</h3>
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
<h3>Key Indicators: West Pharmaceutical Servs's Financial Health</h3>
Revenue Growth: West Pharmaceutical Servs's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 3.29%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 38.01%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): West Pharmaceutical Servs's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.85.
</li>
</ul>
Debt Management: West Pharmaceutical Servs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 45.67 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 9.19 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 30.6, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000105770">Check Out The Full List Of West Pharmaceutical Servs's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Activity Spotlight: Silji Abraham Acquires In West Pharmaceutical Servs Stock Options

A noteworthy insider acquisition was disclosed on February 22, as MacKay, SVP at West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), reported the acquisition of stock options for 2,411 shares.
What Happened: MacKay, SVP at West Pharmaceutical Servs, acquired stock options for 2,411 shares of WST. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000105770/000112760224006398//Archives/edgar/data/105770/000112760224006398/0001127602-24-006398-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The options allow MacKay to buy the company's stock at $350.18 per share.
During Friday's morning session, West Pharmaceutical Servs shares down by 0.0%, currently priced at $359.9. Considering the current price, MacKay's 2,411 shares have a total value of $23,434.
<h3>Discovering West Pharmaceutical Servs: A Closer Look</h3>
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
<h3>Financial Milestones: West Pharmaceutical Servs's Journey</h3>
Revenue Growth: West Pharmaceutical Servs's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 3.29%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 38.01%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 1.85, West Pharmaceutical Servs showcases strong earnings per share.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 45.67 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 9.19, West Pharmaceutical Servs's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): West Pharmaceutical Servs's EV/EBITDA ratio stands at 30.6, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000105770">Check Out The Full List Of West Pharmaceutical Servs's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Capitalizing In Growth Prospects, Banks Kimberly MacKay Acquires In West Pharmaceutical Servs Stock Options

In a new SEC filing on February 22, it was unveiled that ReissClark, Chief Commercial Officer at West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), acquired stock options for 2,411 shares.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000105770/000112760224006409//Archives/edgar/data/105770/000112760224006409/0001127602-24-006409-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that ReissClark, Chief Commercial Officer at West Pharmaceutical Servs, a company in the Health Care sector, acquired stock options for 2,411 shares of WST. The options allow ReissClark to buy the company's stock at $350.18 per share.
West Pharmaceutical Servs shares are currently trading down by 0.0%, with a current price of $359.9 as of Friday morning. This brings the total value of ReissClark's 2,411 shares to $23,434.
<h3>Discovering West Pharmaceutical Servs: A Closer Look</h3>
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
<h3>Financial Milestones: West Pharmaceutical Servs's Journey</h3>
Revenue Growth: West Pharmaceutical Servs displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 3.29%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: With a low gross margin of 38.01%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 1.85, West Pharmaceutical Servs showcases strong earnings per share.
</li>
</ul>
Debt Management: West Pharmaceutical Servs's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 45.67, West Pharmaceutical Servs's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 9.19 is above industry norms, reflecting an elevated valuation for West Pharmaceutical Servs's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): West Pharmaceutical Servs's EV/EBITDA ratio stands at 30.6, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000105770">Check Out The Full List Of West Pharmaceutical Servs's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cindy ReissClark Exhibits Confidence With An Acquisition Of West Pharmaceutical Servs Stock Options

In a recent SEC filing, it was disclosed that Chad Winters, VP at West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), made a noteworthy acquisition of company stock options on February 22,.
What Happened: Winters, VP at West Pharmaceutical Servs, engaged in a derivative transaction according to a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0000105770/000112760224006414//Archives/edgar/data/105770/000112760224006414/0001127602-24-006414-index.htm">U.S. Securities and Exchange Commission</a>. This involved the acquisition of stock options for 1,020 shares of WST, providing the right to purchase the company's stock at an exercise price of $350.18 per share.
During Friday's morning session, West Pharmaceutical Servs shares down by 0.0%, currently priced at $359.9. Considering the current price, Winters's 1,020 shares have a total value of $9,914.
<h3>Get to Know West Pharmaceutical Servs Better</h3>
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
<h3>West Pharmaceutical Servs's Economic Impact: An Analysis</h3>
Positive Revenue Trend: Examining West Pharmaceutical Servs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.29% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 38.01%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): West Pharmaceutical Servs's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 1.85.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.11, West Pharmaceutical Servs adopts a prudent financial strategy, indicating a balanced approach to debt management.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 45.67 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 9.19, West Pharmaceutical Servs's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 30.6, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Deciphering Transaction Codes in Insider Filings</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates grant, award or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000105770">Check Out The Full List Of West Pharmaceutical Servs's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chad Winters Expands Holdings With West Pharmaceutical Servs Stock Options

U.S. stocks broadly surged on Thursday, marking a two-day rebound after the Tuesday market turmoil triggered by a stronger-than-expected inflation report. Investors honed in on robust corporate earnings data while drawing positive insights from a disappointing January retail sales report, reigniting speculation about <a href="https://www.benzinga.com/markets/equities/24/02/37156844/retail-sales-sink-in-january-manufacturing-indicators-improve-jobless-claims-fall-thursdays-econ">potential Fed interest rate cuts.</a>
The S&amp;P 500 surged back above 5,000 points, while the Nasdaq 100 paused for a breather at 17,800. 
Small caps outshined large caps, with the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallying 1.4% on top of Wednesday&#8217;s 2.4% surge. 
The dollar moved slightly lower, causing commodities to regain some ground. Gold, as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), surged back above $2,000, while silver rallied 2.3%. 
Crude oil prices, as tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), rose 1.9% to $78 a barrel. 
<h2 class="wp-block-heading">Thursday&#8217;s Performance In Major Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices &amp; ETFs</td>
<td>Price</td>
<td>1-day %</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,020.13</td>
<td>1.5%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>38,620.08</td>
<td>0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,011.47</td>
<td>0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>17,784.05</td>
<td>-0.1</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was 0.3% higher to $500 the SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.6% to $386.34 and the tech-heavy Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) held at $433.15, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>. 
The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), outperformed, up 2.2%, while the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) was the laggard, down 0.5%. 
<h2 class="wp-block-heading">Thursday&#8217;s Stock Movers</h2>
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 4% amid rising optimism that the Biden administration could enact proposed Environmental Protection Agency regulations next month that might speed up the electric vehicle transition. </li>
<li>Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) rose over 6% after the bank announced the the Office of the Comptroller of the Currency concluded a 2016 consent order over its sales practices misconduct. </li>
<li>CBRE Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) rallied 8% on stronger-than-expected fourth-quarter results. </li>
<li>Shares of Deer &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) fell 6% as the company unveiled a disappointing outlook for the first quarter. </li>
<li>Other companies reacting to earnings are Antero Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>), up 10%, Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), down 2.5%, Zebra Technologies Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NYSE">ZBRA</a>), up 11%, West Pharmaceuticals Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), down 14%, Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>), down 15%, AppLovin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APP#NYSE">APP</a>), up 21%, Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>), up 31%, YETI Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NASDAQ">YETI</a>), down 15%, Penn Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>), down 14% and Tripadvisor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>), up 10%. </li>
</ul>
Read now: <a href="https://www.benzinga.com/top-stories/24/02/37163602/spotlight-on-the-ai-5-microsoft-tsmc-broadcom-nvidia-and-amd">Spotlight On The AI 5: Microsoft, TSMC, Broadcom, Nvidia And AMD</a>
Illustration created using artificial intelligence via MidJourney.

S&P Reclaims 5,000 As Disappointing Retail Sales Put Fed Cuts Back On Track, Small Caps Shine: What's Driving Markets Thursday?

Shares of Herbalife Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NYSE">HLF</a>) fell sharply in today&rsquo;s session following <a href="https://www.benzinga.com/quote/HLF/earnings">weak quarterly earnings</a>.
Herbalife posted adjusted earnings of 28 cents per share, missing market estimates of 39 cents per share. The company&rsquo;s quarterly sales came in at $1.22 billion versus expectations of $1.19 billion.
Herbalife shares dipped 35.7% to $7.55 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>JX Luxventure Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jxjt#NASDAQ">JXJT</a>) shares jumped 377% to $6.21 following H1 results.</li>
<li>Dunxin Financial Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxf#NYSE">DXF</a>) surged 204% to $1.11 after gaining around 5% on Wednesday.</li>
<li>China Natural Resources, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chnr#NASDAQ">CHNR</a>) jumped 143% to $2.68 after gaining around 10% on Wednesday.</li>
<li>The Children&#39;s Place, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plce#NASDAQ">PLCE</a>) rose 101% to $29.23.</li>
<li>Nano-X Imaging Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nnox#NASDAQ">NNOX</a>) shares climbed 54.7% to $9.84. Nvidia reported a 59,632 share stake in Nano X Imaging.</li>
<li>RiskOn International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roi#NASDAQ">ROI</a>) gained 54% to $0.1710.</li>
<li>SoundHound AI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soun#NASDAQ">SOUN</a>) gained 53% to $3.4499. According to data from Benzinga Pro, BlackRock reported a 5.6% passive stake in SoundHound AI after the market close. Traders also appear to be circling a filing from Nvidia in which the company disclosed positions in several companies, including SoundHound AI.</li>
<li>Orgenesis Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/orgs#NASDAQ">ORGS</a>) climbed 30.2% to $0.4362. Orgenesis 10% owner Jacob Safier acquired a total of 365,140 shares at an average price of $0.58.</li>
<li>Pegasystems Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pega#NASDAQ">PEGA</a>) jumped 27.8% to $64.84 after the company reported better-than-expected fourth-quarter financial results and issued FY24 EPS and revenue guidance above estimates.</li>
<li>JFrog Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frog#NASDAQ">FROG</a>) shares gained 27% to $47.09 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter adjusted EPS and revenue guidance above estimates.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) rose 26% to $1.1800.</li>
<li>American Well Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amwl#NASDAQ">AMWL</a>) jumped 25% to $1.39 following quarterly results.</li>
<li>Datasea Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtss#NASDAQ">DTSS</a>) gained 25% to $11.24. DataSea announced a $30 million 5G multimodal communication technology service agreement.</li>
<li>AppLovin Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/app#NASDAQ">APP</a>) rose 22% to $57.16 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Ultralife Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ulbi#NASDAQ">ULBI</a>) gained 21.4% to $9.60 following upbeat quarterly results.</li>
<li>Shake Shack Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shak#NYSE">SHAK</a>) rose 18.6% to $92.60 after the company reported better-than-expected quarterly financial results and issued guidance.</li>
<li>Digital World Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dwac#NASDAQ">DWAC</a>) jumped 18.6% to $51.65 after the company announced the U.S. Securities and Exchange Commission declared its registration statement on Form S-4 effective.</li>
<li>Sylvamo Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/slvm#NYSE">SLVM</a>) gained 18.5% to $53.94 following upbeat earnings.</li>
<li>DNOW Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dnow#NYSE">DNOW</a>) jumped 18.4% to $11.62 following strong quarterly results.</li>
<li>Express, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/expr#NYSE">EXPR</a>) climbed 18.1% to $2.4111.</li>
<li>Organon &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogn#NYSE">OGN</a>) shares rose 16.5% to $19.07 after the company reported better than expected Q4 2023 earnings and issued 2024 guidance.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) shares surged 15.9% to $1.25 after falling 6% on Wednesday.</li>
<li>Rail Vision Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvsn#NASDAQ">RVSN</a>) gained 15.2% to $6.76.</li>
<li>Organon &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogn#NYSE">OGN</a>) rose 14.9% to $18.80 after the company reported better than expected fourth quarter earnings and issued 2024 guidance.</li>
<li>Zebra Technologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zbra#NASDAQ">ZBRA</a>) rose 14% to $288.44 after the company reported fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li>Appian Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/appn#NASDAQ">APPN</a>) climbed 13.8% to $37.97 after the company reported fourth-quarter financial results above estimates.</li>
<li>Zebra Technologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zbra#NASDAQ">ZBRA</a>) rose 12.7% to $285.24 after the company reported fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li>Informatica Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/infa#NYSE">INFA</a>) gained 12.6% to $33.91 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Patterson-UTI Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pten#NASDAQ">PTEN</a>) rose 12.3% to $11.61 following strong sales.</li>
<li>Reliance Steel &amp; Aluminum Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rs#NYSE">RS</a>) rose 10.4% to $325.15 after the company reported fourth-quarter earnings above estimates and issued above-consensus first-quarter FY24 adjusted EPS.</li>
<li>EPAM Systems, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/epam#NYSE">EPAM</a>) gained 10.3% to $288.44 after the company reported fourth-quarter financial results and issued first-quarter revenue guidance above estimates.</li>
<li>Cognex Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgnx#NASDAQ">CGNX</a>) rose 9.8% to $39.70 following upbeat earnings.</li>
<li>SunPower Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spwr#NASDAQ">SPWR</a>) shares jumped 8.8% to $4.64 after the company announced raising $175 million in new capital financing from TotalEnergies and Global Infrastructure Partners and fourth-quarter financial results below estimates.</li>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) rose 8.6% to $17.82. Lyft recently reported fourth-quarter financial results and issued guidance.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Treasure Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgl#NASDAQ">TGL</a>) fell 45.7% to $0.0862 following second-quarter results.</li>
<li>Beamr Imaging Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmr#NASDAQ">BMR</a>) fell 44% to $9.00.</li>
<li>Earlyworks Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elws#NASDAQ">ELWS</a>) shares fell 39.1% to $0.7979.</li>
<li>Upexi, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upxi#NASDAQ">UPXI</a>) shares declined 30.4% to $0.96 following weak quarterly results.</li>
<li>Telomir Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/telo#NASDAQ">TELO</a>) shares fell 30.1% to $8.31 after jumping around 70% on Wednesday.</li>
<li>Fastly, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsly#NYSE">FSLY</a>) shares tumbled 29.2% to $16.67 after the company reported mixed fourth-quarter financial results.</li>
<li>Cineverse Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnvs#NASDAQ">CNVS</a>) shares fell 27.2% to $1.7120 after the company reported worse-than-expected third-quarter financial results.</li>
<li>Aurinia Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auph#NASDAQ">AUPH</a>) fell 26.1% to $5.89 after the company reported mixed fourth-quarter financial results and said it did not find a buyer after conducting a strategic business review.</li>
<li>Clean Energy Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cety#NASDAQ">CETY</a>) dipped 26% to $0.7989.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) fell 25.4% to $0.9001 after the company posted weak quarterly sales.</li>
<li>Innodata Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inod#NASDAQ">INOD</a>) fell 25.2% to $9.16 after Wolfpack Research issued a report on the company and said it is short the stock.</li>
<li>Sabre Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sabr#NASDAQ">SABR</a>) dipped 23.3% to $3.3850 after the company reported mixed quarterly financial results.</li>
<li>Udemy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/udmy#NASDAQ">UDMY</a>) fell 20.8% to $11.08 after the company reported fourth-quarter financial results.</li>
<li>Nu Skin Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>) shares fell 18.8% to $14.15 after the company reported fourth-quarter financial results.</li>
<li>West Pharmaceutical Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wst#NYSE">WST</a>) fell 18.5% to $332.37 after the company reported mixed fourth-quarter financial results and issued 2024 adjusted EPS and sales guidance below estimates.</li>
<li>Twilio Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/twlo#NYSE">TWLO</a>) dipped 13.8% to $62.29 after the company reported fourth-quarter financial results.</li>
<li>The Manitowoc Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mtw#NYSE">MTW</a>) fell 12.6% to $14.36 following weak earnings.</li>
<li>Manchester United plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/manu#NYSE">MANU</a>) fell 12.1% to $18.90.</li>
<li>Hanesbrands Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hbi#NYSE">HBI</a>) fell 11.6% to $4.17 following weak results.</li>
<li>PENN Entertainment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/penn#NASDAQ">PENN</a>) fell 10.2% to $20.17 following weak results.</li>
<li>Insight Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nsit#NASDAQ">NSIT</a>) dipped 5.5% to $182.10 after the company reported fourth-quarter financial results and issued FY24 EPS guidance below estimates.</li>
<li>Deere &amp; Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/de#NYSE">DE</a>) fell 4.7% to $366.79 after the company reported first-quarter earnings and lowered FY24 net income guidance.</li>
<li>Rollins, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rol#NYSE">ROL</a>) fell 4.1% to $42.42 following quarterly results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37150356/disney-progressive-leidos-and-more-cnbcs-final-trades"> Disney, Progressive, Leidos And More: CNBC&#39;s &#39;Final Trades&#39;</a>

Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

West Pharmaceutical Services Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) fourth-quarter 2023 adjusted EPS came in at $1.83, up 3.4% Y/Y,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $1.78</a>.
Quarterly sales reached $732 million, up 3.3%, missing the consensus estimate of $739.47 million. Organic net&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/n37152072/west-announces-fourth-quarter-and-full-year-2023-results" rel="noreferrer noopener">sales growth was 1.4%</a>.
&#8220;In 2024, we expect moderated organic sales growth as we manage timing of inventory management, especially with our largest customers. We expect headwinds to be more pronounced during the first quarter and less impactful in subsequent quarters. I am pleased that our February order book for the second half of the year is outpacing typical pre-pandemic levels, coupled with customer optimism of certain breakout drug categories and timing of additional high-value product device capacity, all of which underscore our expectation of a stronger second half organic sales growth,&#8221; said Eric Green, President, CEP and Chairman.
In the fourth quarter of 2023, the Proprietary Products Segment&#8217;s net sales grew by 1.5% to $593.7 million. Organic net sales declined by 0.3%.
Guidance: West Pharmaceutical forecast fiscal year 2024 sales of $3 billion-$3.025 billion, compared to the consensus of $3.21 billion.
The company sees adjusted EPS of $7.50-$7.75 versus the consensus estimate of $8.76.
The quarter&#8217;s revenue fell slightly short of expectations, but the primary concern is the disappointing 2024 guidance, which significantly underperformed market predictions.&nbsp;
Analysts at William Blair write that the issue seems to be an exacerbation or broadening of destocking, as evidenced by earlier references to a slowdown in restocking trends and the mention of timing issues in inventory management, particularly with major customers. 
Given the negative connotations associated with &#8220;destocking&#8221; in the bioprocessing industry&#8217;s recent challenges, there is a need for proactive communication and clarification from West to assure investors that no further cuts are imminent, analysts add. William Blair <a href="https://www.benzinga.com/quote/WST/analyst-ratings" target="_blank" rel="noreferrer noopener">keeps the Outperform rating</a>.
Price Action: WST shares are down 13.9% at $351.21 at last check Thursday.
Now Read: <a href="https://www.benzinga.com/m-a/24/02/37160887/broadcom-sees-boost-from-tiger-globals-entry-signaling-confidence-in-ai-semiconductor-market">Broadcom Sees Boost from Tiger Global&#8217;s Entry, Signaling Confidence in AI Semiconductor Market</a>
Image created using artificial intelligence with MidJourney.

West Pharmaceutical's 2024 Outlook Cautious, Analysts Remain Optimistic

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has risen 8.42% since its last report. The company recently reported that it has 1.16 million shares sold short, which is 2.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1708015516_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.63%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

WIIM

West Pharmaceutical Services shares are trading lower after the company reported mixed Q4 financial results and issued 2024 adjusted EPS and sales guidance below estimates.

West Pharmaceutical Services Expects 2024 Sales Of $3B-$3.025B And Adjusted EPS Of $7.50-$7.75 Versus Consensus Of $3.21B and $8.76, Respectively

West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.78 by 2.81 percent. This is a 3.39 percent increase over earnings of $1.77 per share from the same period last year. The company reported quarterly sales of $732.00 million which missed the analyst consensus estimate of $739.47 million by 1.01 percent. This is a 3.29 percent increase over sales of $708.70 million the same period last year.

West Pharmaceutical Servs Q4 Adjusted EPS $1.83 Beats $1.78 Estimate, Sales $732.00M Miss $739.47M Estimate

AGIO

ALKS

ALLT

ALNY

AMAT

AORT

ARCH

ATRC

BJRI

BLZE

BPMC

CLBT

CMBM

COHU

COIN

CORT

CRBG

CROX

CWST

DASH

DKNG

EDRY

ELME

GLOB

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HOUS

HTGC

IDCC

IRDM

IREN

IRWD

ITGR

JMIA

KELYA

KELYB

KNSL

LBTYA

LECO

Laboratory Corporation Of America Holdings

MERC

MTRN

MYTE

NVMI

OPEN

ORAN

OTLY

PACB

PCOR

PDFS

PRAA

PRTA

RARE

RELX

ROKU

RPRX

Earnings Scheduled For February 15, 2024

Keybanc has decided to maintain its Overweight rating of West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) and raise its price target from $440.00 to $470.00.
Shares of West Pharmaceutical Servs are trading down 0.48% over the last 24 hours, at $404.67 per share.
A move to $470.00 would account for a 16.14% increase from the current share price.
<h3>About West Pharmaceutical Servs</h3>
West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (82% of 2021 sales) and contract-manufactured products (18%). It generates 55% of its revenue from international markets and 45% from the United States.
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Keybanc Maintains Overweight Rating for West Pharmaceutical Servs: Here's What You Need To Know

Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Overweight and raises the price target from $440 to $470.

Price Target

Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $470

On CNBC&rsquo;s &quot;<a href="https://www.cnbc.com/video/2024/02/07/final-trades-west-pharma-sonos-thermo-fisher-and-transdigm.html">Halftime Report Final Trades</a>,&quot; Steve Weiss of Short Hills Capital Partners named&nbsp;TransDigm Group Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdg#NYSE">TDG</a>), which is scheduled to release <a href="https://www.benzinga.com/quote/TDG/earnings"> quarterly earnings today. </a>
TransDigm Group is expected to report fiscal 2024 first quarter earnings before the opening bell on Feb. 8, 2024. Analysts expect the company to report quarterly earnings at $6.41 per share, up from year-ago earnings of $4.58 per share. The company is projected to post revenue of 1.68 billion for the recent quarter.
Brian Belski of BMO Capital Markets said he loves Sonos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sono#NASDAQ">SONO</a>).
Sonos reported better-than-expected first-quarter financial results. The company posted adjusted earnings of 84 cents per share, beating market estimates of 39 cents per share. Its quarterly sales came in at $612.87 million, topping expectations of $587.20 million.
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
Karen Firestone of Aureus Asset Management picked Thermo Fisher Scientific Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tmo#NYSE">TMO</a>).
Thermo Fisher Scientific posted a fourth-quarter revenue of $10.89 billion, down 5% year-on-year (Y/Y), beating the <a href="https://www.benzinga.com/news/earnings/24/01/36867922/medical-equipment-maker-thermo-fisher-scientific-clocks-7-decline-in-q4-organic-sales-issues-subdue">consensus of $10.73 billion</a>.
Joe Terranova of Virtus Investment Partners named West Pharmaceutical Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wst#NYSE">WST</a>) as his final trade.
West Pharmaceutical Services is expected to release fourth-quarter and full-year 2023 financial results before the opening bell on Feb. 15, 2024.
<h3>Price Action:</h3>
<ul>
<li>TransDigm shares gained 0.6% to close at $1,147.01 on Wednesday.</li>
<li>Sonos shares jumped 17.1% to settle at $19.28 during Wednesday&rsquo;s session.</li>
<li>Shares of Thermo Fisher Scientific fell 1.4% to settle at $552.31 on Wednesday.</li>
<li>West Pharmaceutical shares gained 3.7% to close at $413.00 on Wednesday.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/36973306/jim-cramer-says-this-real-estate-stock-is-done-going-down-thats-a-gutsy-call-by-me"> Jim Cramer Says This Real Estate Stock Is &#39;Done Going Down, That&#39;s A Gutsy Call By Me&#39; </a>
Image: Shutterstock

Long Ideas

Media

SONO

TransDigm, West Pharmaceutical, Thermo Fisher Scientific And A Tech Company On CNBC's 'Final Trades'

West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) has outperformed the market over the past 10 years by 12.48% on an annualized basis producing an average annual return of 23.21%. Currently, West Pharmaceutical Servs has a market capitalization of $27.35 billion. 
Buying $1000 In WST: If an investor had bought $1000 of WST stock 10 years ago, it would be worth $8,051.19 today based on a price of $369.63 for WST at the time of writing.
<h3>West Pharmaceutical Servs's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1706803218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning West Pharmaceutical Servs Stock In The Last 10 Years

West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) has outperformed the market over the past 15 years by 10.08% on an annualized basis producing an average annual return of 21.95%. Currently, West Pharmaceutical Servs has a market capitalization of $24.90 billion. 
Buying $1000 In WST: If an investor had bought $1000 of WST stock 15 years ago, it would be worth $20,063.83 today based on a price of $336.47 for WST at the time of writing.
<h3>West Pharmaceutical Servs's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1704722412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth $20,000 Today

West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) has outperformed the market over the past 15 years by 9.84% on an annualized basis producing an average annual return of 21.63%. Currently, West Pharmaceutical Servs has a market capitalization of $26.26 billion. 
Buying $100 In WST: If an investor had bought $100 of WST stock 15 years ago, it would be worth $1,977.33 today based on a price of $354.93 for WST at the time of writing.
<h3>West Pharmaceutical Servs's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2023/1703521813_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In West Pharmaceutical Servs 15 Years Ago Would Be Worth Today

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Recent trends in the stock market have seen a shift in investor interest from tech giants, known as the Magnificent 7, towards pharmaceutical companies, particularly those involved in weight-loss drugs. But, it&rsquo;s important to identify which pharma stocks to sell before they plummet, as not all will benefit equally from the hype.



As a result, pharmaceutical companies like Eli Lilly (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>), Pfizer (NYSE:<a href="https://investorplace.com/stock-quotes/pfe-stock-quote/">PFE</a>) and Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) are attracting retail investors&rsquo; attention given their portfolio exposure to the weight-loss trend. This shift became pronounced when Novo Nordisk&rsquo;s shares hit a record high after announcing updates on a new obesity drug, surpassing Tesla (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>) in market cap ranking.&nbsp;



Similarly, Eli Lilly has also been in the spotlight, with Bank of America (NYSE:<a href="https://investorplace.com/stock-quotes/bac-stock-quote/">BAC</a>) setting a $1,000 price target based on the sales potential of its weight-loss drug, sparking speculation about it becoming the first trillion-dollar drug company.



While these mega-cap companies are seeing their shares soar, others have found 2024 a difficult year.



Which pharma stocks to sell during this market boom cycle?



<h2>ACADIA Pharmaceuticals (ACAD)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/03/acadia-pharmaceuticals.png"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/acadia-pharmaceuticals-300x169.png" alt="pharma stocks to sell Acadia Pharma (ACAD)"></a>ACADIA Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/acad-stock-quote/">ACAD</a>) is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs designed to address unmet medical needs in central nervous system (CNS) disorders.&nbsp;



The company&rsquo;s flagship product, Nuplazid (pimavanserin), is the first and only medication approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson&rsquo;s disease psychosis.



Headquartered in San Diego, California, ACADIA is dedicated to advancing its pipeline of innovative therapies targeting conditions such as schizophrenia, dementia-related psychosis and major depressive disorder.&nbsp;



This week, Acadia stock <a href="https://ir.acadia.com/news-releases/news-release-details/acadia-pharmaceuticals-announces-top-line-results-phase-3-1" target="_blank">fell more than 17%</a> in a single day following the announcement that the company has decided against conducting further trials for pimavanserin. This decision came after the drug, aimed at treating schizophrenia, did not achieve the primary goal set for its Phase 3 study.



Mizuho analysts <a href="https://www.investing.com/news/stock-market-news/acadia-pharma-to-stop-pimavanserin-trials-after-failure-432SI-3334673" target="_blank">downgraded</a> their rating on ACAD, citing trial results.



&ldquo;Given the failed ADVANCE-2 trial, we remove our sales forecast for Nuplazid in negative symptoms of schizophrenia (NSS),&rdquo; said analysts at the firm. &ldquo;Our new $25 PT incorporates value for Nuplazid in Parkinson&rsquo;s disease psychosis (PDP), Daybue with ~$1B peak sales, and potential Nuplazid IP extension into 2038 for PDP.&rdquo;



<h2>Amylyx Pharmaceuticals (AMLX)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/03/amylyx-pharmaceuticals.png"><img width="300" height="203" src="https://investorplace.com/wp-content/uploads/2024/03/amylyx-pharmaceuticals-300x203.png" alt="Pharma stocks to sell Amylyx Pharmaceuticals (AMLX) "></a>Amylyx Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/amlx-stock-quote/">AMLX</a>) is a biopharmaceutical company developing new treatments for neurodegenerative diseases. The company is known for its work in creating innovative therapies aimed at slowing the progression of debilitating conditions like Amyotrophic Lateral Sclerosis (ALS) and other motor neuron diseases.&nbsp;



One of their notable products, AMX0035, has garnered attention for its potential in treating ALS, showing promising results in clinical trials. However, the company&rsquo;s stock fell more than 80% last week to an all-time low following <a href="https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-topline-results-global-phase-3" target="_blank">disappointing results</a> from a trial of its ALS drug, which failed to show patient benefits.



This outcome raises concerns that U.S. regulators might have endorsed an ineffective treatment, casting doubt on the drug&rsquo;s future prospects and the company&rsquo;s valuation. As a result, investors are likely to avoid Amylyx Pharmaceuticals, given the high uncertainty.&nbsp;



The company disclosed that there was no notable difference in the primary endpoint results between patients treated with the drug and those given a placebo in the trial. This outcome aligns with the worst-case scenario previously outlined by Amylyx, making Amylyx Pharmaceuticals one of the top pharma stocks to sell.



<h2>West Pharmaceutical Services (WST)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/wst-stock-1-300x169.jpg" alt="The West Pharmaceutical Services (WST) logo is displayed on a smartphone screen."><div>Source: rafapress / Shutterstock.com</div></div>West Pharmaceutical Services (NYSE:<a href="https://investorplace.com/stock-quotes/wst-stock-quote/">WST</a>), one of the three pharma stocks to sell, is a major global manufacturer specializing in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines.&nbsp;



The company&rsquo;s products include stoppers and seals for vials, as well as syringe and cartridge components, serving the pharmaceutical, biotech, and generic drug industries. The company&rsquo;s stock faced a sharp decline recently after it offered a bleak forecast for 2024.&nbsp;



Despite previous expectations for a 7% to 9% increase in sales this year, the company anticipates only a 2% to 3% growth next year, citing a reduction in client purchases. The anticipated adjusted diluted earnings for 2024 <a href="https://tokenist.com/west-pharmaceutical-wst-sets-2024-eps-guidance-at-7-50-7-75/" target="_blank">range from $7.50 to $7.75 per share</a>, significantly lower than the expected $8.77.&nbsp;



Furthermore, projected net sales are between $3 billion and $3.1 billion, falling short of the anticipated $3.2 billion. The company reported $732 million in revenue for the last quarter, missing the $739 million forecast, although adjusted earnings per share exceeded expectations at $1.83.&nbsp;



The pharma company attributes the slowdown to inventory management changes among its major customers but anticipates an improvement in business after the first quarter. However, the sudden shift in management&rsquo;s outlook has left investors wary.



&ldquo;It appears that destocking has worsened, or broadened, or both,&rdquo; William Blair analyst Matt Larew <a href="https://www.barrons.com/articles/west-pharmaceutical-earnings-stock-47867619" target="_blank">wrote</a> in a Thursday morning note. &ldquo;West will have to work hard and fast to put some guard rails around the timeline and magnitude here and effectively communicate that there are no further cuts coming.&rdquo;



On the date of publication, Shane Neagle did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Shane Neagle is fascinated by the ways in which technology is poised to disrupt investing. He specializes in fundamental analysis and growth investing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/3-pharma-stocks-to-sell-in-march-before-they-crash-burn/">3 Pharma Stocks to Sell in March Before They Crash &amp; Burn</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Pharma Stocks to Sell in March Before They Crash & Burn

West Pharmaceutical Services Inc. (WST) is near the top in its industry group according to InvestorsObserver. WST gets an overall rating of 51. That means it scores higher than 51 percent of stocks. West Pharmaceutical Services Inc. gets a 77 rank in the Medical Instruments and Supplies industry. Medical Instruments and Su

Is West Pharmaceutical Services Inc. (WST) a Bad Choice in Medical Instruments & Supplies Monday?